HIROTSU Bioscience Supports Japan’s New Health Guidelines with Scientifically Validated Cancer Screening

2025.04.08

Japan’s Ministry of Health, Labour and Welfare (MHLW) recently updated its Guidelines for New Business Activities in the Healthy Life Expectancy Extension Industry Sector, reinforcing the need for preventive health services to avoid misleading consumers with unverified medical claims.

HIROTSU Bioscience fully supports these revisions and remains committed to scientific integrity and regulatory compliance in its services. Our non-invasive N-NOSE cancer screening test is grounded in extensive clinical research and is clearly positioned as a screening tool—not a diagnostic test.

The updated guidelines emphasize that consumer-oriented health technologies must be transparent about their purpose and backed by scientific evidence. As a leader in early cancer risk detection, we welcome this regulatory clarity and view it as an opportunity to strengthen public trust in our offerings.

We will continue to deliver reliable, evidence-based services that contribute to longer, healthier lives—while adhering to all applicable laws and health standards.